Search

Helsinn Healthcare SA NK-1 Antagonist Patent Granted Apr 21

USPTO granted Patent US12606527B2 to Helsinn Healthcare SA on April 21, 2026, for crystalline forms of an NK-1 antagonist useful in treating induced vomiting and other disorders. The patent application (18772244) was filed July 14, 2024, and contains 18 claims classified under CPC C07D 213/75 and related pharmaceutical categories.